Program Description

Overall Program Objectives/Discussion Topics

This CME conference is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease and practicing clinicians together to improve the care of patients at a high risk of cardiovascular, metabolic, and kidney diseases. This program is designed to evaluate the clinical science aspects of diabetes, obesity, and CVD, focusing on the heart and kidney in diabetes. The goal is to develop appropriate, comprehensive clinical management plans aligning endocrinologists, cardiologists, nephrologists and all other interested clinicians in their understandings of the impact of diabetes and CVD outcome trials on the clinical management of these very high-risk patients.

Upon completion of this meeting, participants should be able to:

  • Discuss the role of incretins in the management of obesity, diabetes, and its complications

  • Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1-RAs to reduce cardiovascular mortality in patients with T2D

  • Evaluate the evidence supporting the use of SGLT2 inhibitors for HF prevention

  • Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome

  • Evaluate the extent of macro and microvascular disease in diabetes and obesity

  • Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as glucose

  • Discuss changes in lipid management guidelines

  • Evaluate the impact on the clinical practice of new CV outcome trials in patients with diabetes, including CANVAS, LEADER, SUSTAIN 6, and EMPA-REG

  • Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes

  • Implement the best practices for the management of HFrEF

  • Describe the relationship between diabetes, obesity, and congestive heart failure

  • Describe the role of PCSK9 in lipid elevations and their potential contributions to vascular disease

  • Understand the mechanism of action of PCSK9 inhibitors and CETP inhibitors and their impact on CVD

  • Design appropriate insulin-based therapeutic regimens for patients with type 2 diabetes

  • Describe obesity management based on a complications-centric model

  • Evaluate bariatric procedures and surgery as well as devices, and their effect on weight loss, hormones, and long-term outcomes

  • Describe optimal use of glucose monitoring devices

Initiative/Goal
  • To develop a platform to address the clinical science of the Heart in Diabetes

  • To identify the implications of state-of-the-art clinical research on cardiovascular, liver, and kidney disease in diabetes

  • To further advance the discussion between Cardiologists, Endocrinologists, Nephrologists, Lipidologists, and other interested clinicians, while developing an ongoing interaction in the management and prevention of heart disease in diabetes and cardiometabolic conditions

Target Audience

This educational initiative is designed for endocrinologists, cardiologists, diabetologists, nephrologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

18372 Clark St.

Suite 212

Tarzana, CA 91356

info@tmioa.com

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter